156 related articles for article (PubMed ID: 24525658)
1. The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2014 Apr; 34(2):256-60. PubMed ID: 24525658
[TBL] [Abstract][Full Text] [Related]
2. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
3. Quetiapine serum concentrations in psychiatric patients: the influence of comedication.
Hasselstrøm J; Linnet K
Ther Drug Monit; 2004 Oct; 26(5):486-91. PubMed ID: 15385830
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients.
Bakken GV; Rudberg I; Molden E; Refsum H; Hermann M
Ther Drug Monit; 2011 Apr; 33(2):222-6. PubMed ID: 21383647
[TBL] [Abstract][Full Text] [Related]
5. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.
Grimm SW; Richtand NM; Winter HR; Stams KR; Reele SB
Br J Clin Pharmacol; 2006 Jan; 61(1):58-69. PubMed ID: 16390352
[TBL] [Abstract][Full Text] [Related]
6. Metabolic mechanism of quetiapine in vivo with clinical therapeutic dose.
Li KY; Li X; Cheng ZN; Li HD
Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):83-6. PubMed ID: 15834460
[TBL] [Abstract][Full Text] [Related]
7. 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.
Gjestad C; Haslemo T; Andreassen OA; Molden E
Br J Clin Pharmacol; 2017 Nov; 83(11):2398-2405. PubMed ID: 28585378
[TBL] [Abstract][Full Text] [Related]
8. Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6.
Khazaal Y; Preisig M; Chatton A; Kaufmann N; Bilancioni R; Eap CB
Psychiatr Q; 2013 Sep; 84(3):329-35. PubMed ID: 23230007
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5.
Bakken GV; Rudberg I; Christensen H; Molden E; Refsum H; Hermann M
Drug Metab Dispos; 2009 Feb; 37(2):254-8. PubMed ID: 19022943
[TBL] [Abstract][Full Text] [Related]
10. Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers.
Kim KA; Joo HJ; Lee HM; Park JY
Pharmacogenet Genomics; 2014 Jan; 24(1):35-42. PubMed ID: 24240480
[TBL] [Abstract][Full Text] [Related]
11. Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients.
Bakken GV; Molden E; Hermann M
Ther Drug Monit; 2015 Apr; 37(2):256-61. PubMed ID: 25254417
[TBL] [Abstract][Full Text] [Related]
12. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
Potkin SG; Preskorn S; Hochfeld M; Meng X
J Clin Psychopharmacol; 2013 Feb; 33(1):3-10. PubMed ID: 23277250
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.
DeVane CL; Nemeroff CB
Clin Pharmacokinet; 2001; 40(7):509-22. PubMed ID: 11510628
[TBL] [Abstract][Full Text] [Related]
15. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients.
Elens L; Bouamar R; Hesselink DA; Haufroid V; van Gelder T; van Schaik RH
Pharmacogenet Genomics; 2012 May; 22(5):373-80. PubMed ID: 22388796
[TBL] [Abstract][Full Text] [Related]
16. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
[TBL] [Abstract][Full Text] [Related]
17. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
18. Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents.
Johnson TN; Zhou D; Bui KH
Biopharm Drug Dispos; 2014 Sep; 35(6):341-52. PubMed ID: 24797229
[TBL] [Abstract][Full Text] [Related]
19. Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients.
Yousef AM; Qosa H; Bulatova N; Abuhaliema A; Almadhoun H; Khayyat G; Olemat M
Iran J Kidney Dis; 2016 May; 10(3):156-63. PubMed ID: 27225724
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment.
Shilbayeh SA; Sy SK; Melhem M; Zmeili R; Derendorf H
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):387-94. PubMed ID: 27137148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
